In:
International Journal of Cancer, Wiley, Vol. 148, No. 11 ( 2021-06), p. 2789-2798
Abstract:
What's new? Clinical trial data support the use of nivolumab in melanoma patients, and the drug received a Temporary Authorization for Use in France. Here, the authors present real‐world clinical data on the safety and efficacy of nivolumab collected from 400 patients with unresectable or metastatic melanoma. They found that the safety and efficacy in the real world context was consistent with the profile reported in phase 3 trials. The study also includes data from some sub‐populations that may have been underrepresented in the clinical trials.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Bookmarklink